Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clorethate SCHEMBL41346 | 0.85 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL7148590 | 0.82 | TSHR (0.37) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL4290461 | 0.82 | CHRM2 (0.33) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL9261057 | 0.78 | LMNA (0.32) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL22228982 | 0.76 | CHRM2 (0.35) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL877905 | 0.75 | NAAA (0.47) | — | |
| SCHEMBL9265748 | 0.75 | LMNA (0.37) | — | |
| SCHEMBL4389209 | 0.74 | CHRM2 (0.34) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL8083410 | 0.74 | HTT (0.48) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL575139 | 0.74 | ALDH1A1 (0.62) | CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548694-B2 | Anticoagulants | HOFFMAN-LA ROCHE INC. | 2003-04-15 | — | — | US | claimed |
| EP-1289939-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-12 | — | — | EP | claimed |
| US-20020004608-A1 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | US | claimed |
| WO-2001090051-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-29 | — | — | WO | claimed |
| US-6548694-B2 | Anticoagulants | HOFFMAN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020004608-A1 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004608-A1 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | GLS, SLC6A5, GLRA1 | CHRM2 2886/4885CHRM4 1878/4885CHRM1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.